Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURA3: osimertinib versus platinum-pemetrexed chemotherapy in T790M-positive advanced non-small cell lung cancer after prior EGFR-TKI
jRCT2080222601Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of osimertinib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222601.